Among the other known multiple bDMARDs used in the treatment of RA according to the EULAR guidelines, CTLA4-Ig fusion protein (CTLA4-Ig, abatacept) has proved to modulate the immune response thanks to its innovative pharmacodynamics [30–32]. This evidence concerns the gene CTLA4 and rheumatoid arthritis.